Fact Source: Financial Supervisory Service DART / 2026-01-21
Disclosure Type: Earnings Forecast and Projections based on Consolidated Financial Statements (Voluntary Disclosure)
💡 3-Second Summary
Samsung Biologics has announced its consolidated revenue guidance for the fiscal year 2026 at approximately KRW 5.32T. This figure represents the median value of its projected growth range (+15% to +20% year-over-year); forecast figures for operating profit and net income were not provided in this filing.
📊 1. [Key Disclosure Content & Major Figures Summary]
- FY2026 Consolidated Earnings Forecast (Unit: KRW 100 Millions):
- Target Period: 2026-01-01 ~ 2026-12-31
- Projected Revenue: KRW 53,200
- Operating Profit / Profit Before Tax / Net Income: Not Provided (-)
- Basis of Projections: Market outlook and corporate business plan.
- Revenue Calculation Methodology: The FY2026 revenue target is anchored as the median value within the projected revenue range of +15% to +20% compared to the prior year (※ The baseline FY2025 revenue stands at KRW 45,570 hundred million).
- Discrepancy Between Recent Forecast and Actual Results (FY2025):
- Forecasted Revenue: KRW 57,978 hundred million (Guidance including Samsung Bioepis, published prior to the corporate spin-off).
- Actual Revenue: KRW 45,570 hundred million (Performance excluding Samsung Bioepis, reflecting the post-spin-off structure).
- Discrepancy Rate: -21.4% (Operating profit and net income values are not provided).
- Information Disclosure Details: Delivered to domestic and international investors by the IR team on January 21, 2026, at 16:30 KST. The disclosure does not state specific reasons for the change in earnings performance.
📈 2. [Expert View: What This Disclosure Means for Investors]
This regulatory filing is a voluntary corporate disclosure meant to provide international markets with management’s forward-looking quantitative revenue milestones for the upcoming year. The foundational fact for investors to evaluate is the revenue milestone of KRW 5.32T, which indicates an underlying business strategy aimed at securing meaningful top-line expansion of +15% to +20% against the FY2025 baseline (KRW 4.56T). However, because profitability milestones such as operating profit or net income projections remain entirely undisclosed, analyzing the short-term margin evolution remains restricted.
Furthermore, historical data shows a notable discrepancy of -21.4% between the FY2025 guidance and the actual recorded revenue. The original disclosure notes that this gap stems from structural perimeters—specifically, the pre-spin-off inclusion versus the post-spin-off exclusion of Samsung Bioepis. Given that these figures represent corporate projections under current operational plans, the final realized results carry a potential impact that could cause deviations based on shifts in market conditions or macro environments. Investors should avoid interpreting this KRW 5.32T median value as a guaranteed outcome and instead track quarterly revenue progression alongside changing market variables.
📝 Editor’s Comment (by K-STOCK Editor)
The FY2026 revenue guidance issued by Samsung Biologics outlines management’s quantitative roadmap regarding upcoming top-line expansion. Setting the target at KRW 5.32T based on a projected annual growth range of 15% to 20% serves as an indicator that the company’s internal operational planning maintains an upward trajectory. While the historical -21.4% discrepancy in the FY2025 numbers was driven by a major corporate restructuring event—the corporate spin-off of Bioepis—it underscores the reality that forward-looking projections are inherently prone to variances. Because the operating profit line remains blank in this filing, evaluating qualitative margin velocity remains limited; thus, global investors should maintain a measured approach and focus on evaluating quarterly factory utilization rates and order execution metrics moving forward.
📢 Disclaimer & Source Information
Source: This content has been newly structured and written based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the individual investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
